|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.945 USD | +1.20% |
|
+4.79% | +7.45% |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 331.9 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 62.34% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 144.8 | 19.57 | 145.2 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 136.29% | -86.48% | 642.04% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -2.62x | -2.57x | -2.73x |
| PBR | - | - | - | 0.78x | 0.99x | 1.29x | 1.1x | 1.55x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -1.3x | 0.46x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 876x | 681x | 24.6x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 382x | 40.1x | 10.8x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.14x | -0.14x | -0.95x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.15x | -0.14x | -1x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.39x | -0.14x | -0.97x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -72% | -709% | -104% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.112 | -1.134 | -1.066 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.3788 | 0.4875 | 13.49 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -126.9 | -144.2 | -153 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -125.4 | -144.8 | -144.5 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -120.6 | -138.1 | -137 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -187.1 | -312.3 | -186.7 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 2.910 | 2.910 | 2.910 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 114,046 | - | - |
| Announcement Date | 21/09/21 | 01/05/23 | 28/03/24 | 26/03/25 | 16/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.64x | 342.07x | -1.14x | -.--% | 332M | |
| 32.83x | 5.9x | 17.55x | 0.98% | 48.53B | |
| -23.41x | 351.08x | -21.45x | -.--% | 39.87B | |
| 30.42x | 3.04x | 13.11x | -.--% | 38.68B | |
| 46.94x | 4.76x | 30.78x | -.--% | 35.13B | |
| 28.41x | 8.22x | 20.66x | 0.41% | 29.79B | |
| 32.82x | 5.37x | 24.39x | -.--% | 16.11B | |
| 22.67x | 1.99x | 8.61x | 1.17% | 13.61B | |
| 25.33x | 1.86x | 11.4x | -.--% | 12.62B | |
| Average | 21.49x | 80.48x | 11.55x | 0.28% | 26.07B | |
| Weighted average by Cap. | 23.39x | 64.19x | 12.16x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
